Atomo Diagnostics Announces CEO Transition
Key points
- Mr. John Kelly steps down as CEO and Managing Director
- Dr. Cheri Walker appointed as interim CEO
- Transition reflects company's international growth focus
Full summary
Atomo Diagnostics Ltd (ASX: AT1) announced that Mr. John Kelly, the Managing Director and CEO, will step down from his roles effective August 19, 2026. Kelly, a co-founder, played a crucial role in developing the company's core technology and expanding its international presence. Dr. Cheri Walker, a seasoned executive with extensive experience in life science and diagnostics, has been appointed as interim CEO. Walker's US base aligns with the company's focus on international markets, particularly the US and Europe. The Board will initiate a global search for a permanent CEO, while Kelly will support Walker during the transition period.
Summary generated by a large language model. Please interpret with care.